KRAS and type 1 diabetes mellitus: Here we showed that STZ-induced type 1 diabetes, which is characterized by marked hyperglycaemia and insulinopenia without weight gain [35], significantly accelerated tumour progression in a mouse model of Kras–driven PaC.